glp 1 and substance use disorder Glucagon-like peptide-1 receptor agonists risk of disorders among US veterans with type 2 diabetes: cohort study GLP-1 and Substance Use Disorder:

This fusion protein resists enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and slows renal clearance, producing the long half-life that makes once-weekly dosing feasible 2

Medicare Obesity Coverage Expansion (Regulatory): The Centers for Medicare & Medicaid Services (CMS) announced that beginning in April 2026, Medicare will cover GLP-1 medications for beneficiaries with obesity and qualifying comorbidities via the BALANCE Model and Section 402 demonstrations, marking a reversal of the long-standing statutory ban on weight-loss drug coverage

Sp1 transcription factor: A long-standing target in cancer chemotherapy

That keeps pricing predictable, but it also means there is no copay pathway or coverage-based reduction to lower the monthly rate you see